| 3.59 -0.07 (-1.91%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.52 | 1-year : | 8.59 |
| Resists | First : | 5.58 | Second : | 7.36 |
| Pivot price | 4.13  |
|||
| Supports | First : | 2.71 | Second : | 2.25 |
| MAs | MA(5) : | 3.51 | MA(20) : | 4.15  |
| MA(100) : | 2.92 |
MA(250) : | 4.48 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 12.3 |
D(3) : | 9.7 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 13.84 | Low : | 1.47 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARTV ] has closed above bottom band by 28.5%. Bollinger Bands are 67.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.71 - 3.73 | 3.73 - 3.75 |
| Low: | 3.49 - 3.51 | 3.51 - 3.52 |
| Close: | 3.56 - 3.59 | 3.59 - 3.62 |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Mon, 03 Nov 2025
Artiva Biotherapeutics to Host Webcast on Initial Safety and Translational Data for AlloNK in Autoimmune Disease Treatment - Quiver Quantitative
Sat, 01 Nov 2025
ARTV - ARTIVA BIOTHERAPEUTICS INC Latest Stock News & Market Updates - Stock Titan
Thu, 30 Oct 2025
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November - Sahm
Wed, 29 Oct 2025
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Mon, 20 Oct 2025
Artiva Biotherapeutics (ARTV): Evaluating Valuation After FDA Fast Track Milestone for Refractory Rheumatoid Arthritis Therapy - simplywall.st
Sun, 19 Oct 2025
Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 19.8 (%) |
| Held by Institutions | 75.9 (%) |
| Shares Short | 204 (K) |
| Shares Short P.Month | 291 (K) |
| EPS | -6.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -41.6 % |
| Return on Equity (ttm) | -86.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -0.59 |
| PEG Ratio | 0 |
| Price to Book value | 0.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|